Citius Oncology, Inc. (CTOR): Total Assets
$100.94M
As of 2025-09-30
$112.09M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $100.94M | +19.6% | 2025-12-23, Balance as of period end |
| 2024-09-30 | $84.37M | n/a | 2025-12-23, Balance as of period end |
| 2023-12-31 | $72.62M | n/a | 2024-04-16, Balance as of period end |
| 2023-09-30 | $47.73M | n/a | 2024-12-27, Balance as of period end |
| 2022-12-31 | $68.19M | n/m | 2024-04-16, Balance as of period end |
| 2021-12-31 | $126.4K | n/a | 2023-04-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | 2025-09-30 | $100.94M | +19.6% |
| iBio, Inc. (IBIO) | 2026-06-30 | $99.11M | +327.5% |
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | $97.97M | +163.8% |
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $104.23M | +7.8% |
| Immix Biopharma, Inc. (IMMX) | 2025-12-31 | $104.84M | +356.9% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $105.01M | -15.4% |
| Celularity Inc (CELU) | 2025-12-31 | $107.33M | -19.1% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $94.62M | -28.2% |
| Journey Medical Corp (DERM) | 2025-12-31 | $94.59M | +17.9% |
Compare CTOR, IBIO, NERV, TENX side by side · Screen every company in Pharmaceutical Preparations ↗